The aim of this ViiV-funded observational study is to evaluate the birth outcomes of HIV-positive women who are receiving Dolutegravir or other ARV drug regimens in Eswatini.
Data Collection Period: 08/2021 – 09/2023
Publications and Presentations:
- Findings published in Open Forum Infectious Diseases, August 2023: Strengthening the Evidence: Similar Rates of Neural Tube Defects Among Deliveries Regardless of Maternal HIV Status and Dolutegravir Exposure in Hospital Birth Surveillance in Eswatini